Clinical Research Directory
Browse clinical research sites, groups, and studies.
mRNA Vaccine Targeting Epstein-Barr Virus (EBV) in Healthy Young Adults
Sponsor: Vaccine Company, Inc.
Summary
This is an adaptive design Phase 1 clinical trial to evaluate the safety and immunogenicity of VXCO-102 in healthy adult participants.
Official title: A Phase 1, Dose Escalation, Placebo-Controlled, Adaptive-Design Study to Evaluate the Safety and Immunogenicity of VXCO-102, a mRNA Vaccine Targeting Epstein-Barr Virus (EBV) in Healthy Young Adults
Key Details
Gender
All
Age Range
18 Years - 25 Years
Study Type
INTERVENTIONAL
Enrollment
45
Start Date
2026-05-04
Completion Date
2027-08-31
Last Updated
2026-04-29
Healthy Volunteers
Yes
Conditions
Interventions
VXCO-102
Sterile liquid for injection
Placebo
0.9% sodium chloride (BP grade)
Locations (2)
Q-Pharm Pty Ltd/Nucleus Network Pty Ltd
Herston, Queensland, Australia
Nucleus Network Pty Ltd
Melbourne, Victoria, Australia